FDA recent expectations on generic product development: A comprehensive review

The United States Food and Drug Administration (FDA) has significantly evolved its regulatory framework for generic drug development over recent years, introducing new guidance documents, streamlined pathways, and enhanced scientific standards. This review examines the FDA’s current expectations for generic product development, focusing on bioequivalence requirements, complex generic formulations, quality standards, and emerging regulatory pathways. Key developments include the expansion of alternative bioequivalence approaches, enhanced guidance for complex products, implementation of the Generic Drug User Fee Amendments (GDUFA III), and increased focus on pharmaceutical quality metrics. This article provides a comprehensive analysis of these developments and their implications for generic drug manufacturers navigating the current regulatory landscape.